McIlrath & Eck’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $173K | Sell |
6,155
-31
| -0.5% | -$825 | 0.01% | 279 |
|
|
2025
Q4 | $154K | Buy |
6,186
+1,883
| +44% | +$47.5K | 0.01% | 198 |
|
|
2025
Q3 | $110K | Sell |
4,303
-124
| -3% | -$3.06K | 0.01% | 203 |
|
|
2025
Q2 | $107K | Sell |
4,427
-1,427
| -24% | -$33.3K | 0.01% | 194 |
|
|
2025
Q1 | $148K | Buy |
5,854
+156
| +3% | +$4.08K | 0.02% | 152 |
|
|
2024
Q4 | $151K | Sell |
5,698
-596
| -9% | -$16.2K | 0.02% | 139 |
|
|
2024
Q3 | $182K | Sell |
6,294
-813
| -11% | -$23.7K | 0.02% | 128 |
|
|
2024
Q2 | $199K | Buy |
7,107
+104
| +1% | +$2.86K | 0.03% | 114 |
|
|
2024
Q1 | $194K | Sell |
7,003
-354
| -5% | -$9.82K | 0.03% | 117 |
|
|
2023
Q4 | $212K | Sell |
7,357
-359
| -5% | -$10.9K | 0.04% | 111 |
|
|
2023
Q3 | $256K | Sell |
7,716
-601
| -7% | -$21.3K | 0.05% | 101 |
|
|
2023
Q2 | $305K | Sell |
8,317
-965
| -10% | -$37.6K | 0.06% | 90 |
|
|
2023
Q1 | $379K | Buy |
9,282
+1,191
| +15% | +$51.4K | 0.09% | 73 |
|
|
2022
Q4 | $415K | Buy |
8,091
+550
| +7% | +$26.4K | 0.11% | 63 |
|
|
2022
Q3 | $330K | Sell |
7,541
-271
| -3% | -$13.2K | 0.09% | 70 |
|
|
2022
Q2 | $410K | Buy |
7,812
+758
| +11% | +$38.6K | 0.13% | 49 |
|
|
2022
Q1 | $365K | Buy |
7,054
+1
| +0% | +$52 | 0.11% | 55 |
|
|
2021
Q4 | $416K | Sell |
7,053
-516
| -7% | -$25.6K | 0.11% | 55 |
|
|
2021
Q3 | $326K | Buy |
7,569
+59
| +0.8% | +$2.61K | 0.1% | 56 |
|
|
2021
Q2 | $294K | Sell |
7,510
-203
| -3% | -$7.89K | 0.09% | 63 |
|
|
2021
Q1 | $279K | Sell |
7,713
-187
| -2% | -$6.64K | 0.1% | 54 |
|
|
2020
Q4 | $291K | Buy |
7,900
+1,384
| +21% | +$50.8K | 0.11% | 50 |
|
|
2020
Q3 | $227K | Buy |
6,516
+1,411
| +28% | +$49.5K | 0.1% | 50 |
|
|
2020
Q2 | $158K | Buy |
5,105
+1,075
| +27% | +$36.5K | 0.07% | 55 |
|
|
2020
Q1 | $125K | Sell |
4,030
-117
| -3% | -$3.99K | 0.07% | 56 |
|
|
2019
Q4 | $154K | Buy |
4,147
+447
| +12% | +$15.9K | 0.07% | 56 |
|
|
2019
Q3 | $126K | Sell |
3,700
-462
| -11% | -$16.8K | 0.07% | 56 |
|
|
2019
Q2 | $168K | Hold |
4,162
| – | – | 0.09% | 50 |
|
|
2019
Q1 | $168K | Buy |
4,162
+1,057
| +34% | +$42.3K | 0.09% | 50 |
|
|
2018
Q4 | $129K | Buy |
3,105
+188
| +6% | +$7.8K | 0.08% | 54 |
|
|
2018
Q3 | $122K | Buy |
2,917
+388
| +15% | +$14.9K | 0.07% | 64 |
|
|
2018
Q2 | $87K | Buy |
2,529
+34
| +1% | +$1.16K | 0.05% | 80 |
|
|
2018
Q1 | $84K | Sell |
2,495
-2,996
| -55% | -$103K | 0.05% | 91 |
|
|
2017
Q4 | $189K | Buy |
+5,491
| New | +$187K | 0.11% | 53 |
|
Other funds holding PFE
McIlrath & Eck's PFE Position: Q1 2026 in Review
McIlrath & Eck reduced its Pfizer (PFE) stake by 0.5% in Q1 2026, selling an estimated $825 and leaving 6,155 shares worth $173K. The position accounts for 0.01% of the portfolio, ranked #279.
McIlrath & Eck first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $416K in Q4 2021. 2,953 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- McIlrath & Eck held 6,155 shares of Pfizer worth $173K as of Q1 2026.
- McIlrath & Eck sold 31 Pfizer shares in Q1 2026, an estimated $825.
- Pfizer made up 0.01% of McIlrath & Eck's portfolio in Q1 2026, its #279 holding.
- McIlrath & Eck first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- McIlrath & Eck's Pfizer position peaked at $416K in Q4 2021.
- 2,953 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.